Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol
Clinical Cardiology · 2023-10 · 46 (10) · 1220-1226
DOI: 10.1002/clc.24090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, online erschienen am 02.08.2023. Verfasst von Dejan Kojić und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cardiovascular Diseases Dedinje, Belgrade, Serbia. Hauptthemen laut MEDLINE: Propafenone, Ventricular Premature Complexes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Beta‐blockers (BB) or dihydropyridine calcium channel blockers (CCBs) are still the first choices in the treatment of idiopathic premature ventricular complexes (PVCs), with low‐modest efficacy. Antiarrhythmic drugs (AADs) of Ic class are moderate to highly efficient but the evidence on their benefits is still limited.
Aim
To compare effectiveness and safety of flecainide, propafenone, and sotalol in the treatment of symptomatic idiopathic PVCs.
Methods
Our single‐center retrospective study analyzed 104 consecutive patients with 130 medication episodes of frequent idiopathic PVCs treated with AADs flecainide, propafenone (Ic class) or sotalol (III class). The primary outcome was complete/near complete reduction of PVCs after medication episode (PVCs burden reduction >99%), and the secondary outcome was significant PVC burden reduction (≥80%).
Results
The complete/near complete PVCs burden reduction occurred in 31% and was significant in 43% of treated patients. A reduction of PVC burden for >99% was achieved in 56% of patients on flecainide, in 11% of patients on propafenone ( p = .002), and in 21% of patients receiving sotalol ( p = .031). There was no difference between propafenone and sotalol ( p = .174). A reduction of PVC burden for ≥80% was achieved in 64% of patients on flecainide, in 30% of patients on propafenone ( p = .009), and 33% of patients on sotalol ( p = .020). There was no difference between propafenone and sotalol ( p = .661).
Conclusions
The efficacy of AADs class Ic and III in the treatment of idiopathic PVCs was modest. Flecainide was the most effective AAD in the achievement of complete/near complete or significant PVC burden reduction, compared to propafenone and sotalol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Cardiovascular Diseases Dedinje, Belgrade, Serbia.
- Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria.
Zitieren
APA
Kojić, D., Radunović, A., Bukumirić, Z., Rajsic, S., Sušić, M., Marić, M., Žugić, V., Jurčević, R., & Tomović, M. (2023). Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol. Clinical Cardiology, 46(10), 1220-1226. https://doi.org/10.1002/clc.24090
Vancouver
Kojić D, Radunović A, Bukumirić Z, Rajsic S, Sušić M, Marić M, et al. Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol. Clinical Cardiology. 2023;46(10):1220-1226. doi:10.1002/clc.24090
BibTeX
@article{Koji2023,
author = {Kojić, Dejan and Radunović, Anja and Bukumirić, Zoran and Rajsic, Sasa and Sušić, Maša and Marić, Marija and Žugić, Vasko and Jurčević, Ružica and Tomović, Milosav},
title = {Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol},
journal = {Clinical Cardiology},
year = {2023},
volume = {46},
number = {10},
pages = {1220--1226},
doi = {10.1002/clc.24090}
}
EUVIMED